How would you manage a patient with mCRPC with a good clinical and >50% reduction in PSA to Lu-PSMA but evidence of radiographic progression on PSMA PET/CT?  

As no guidelines exist today that incorporates use of PSMA PET to make a decision to change therapy; when changing therapy, I try to use PCWG criteria and the rationale to make a decision. My goal is to switch therapies only when there is clinical or radiographic evidence of clear progression (...